Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6694
Source ID: NCT02433678
Associated Drug: Dapagliflozin
Title: An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
Acronym:
Status: COMPLETED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT02433678/results
Conditions: Type 2 Diabetes
Interventions: DRUG: dapagliflozin|DRUG: Placebo
Outcome Measures: Primary: Difference in the Percent Change in Fasting Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells Activation (DNA Binding Activity) in Mononuclear Cells Before and After Dapagliflozin Use, nuclear factor kappa-light-chain-enhancer of activated B cells measurement through Transcription factor assay, 12 weeks | Secondary: Changes in Expression of Inflammatory Mediators, p47phox in mononuclear cells through real time polymerase chain reaction, 12 Weeks|Changes in Expression of Inflammatory Mediators, Suppressor Of Cytokine Signaling 3 measurement in Mononuclear cells through real time polymerase chain reaction, 12 weeks|Changes in Expression of Inflammatory Mediators, Interleukin 1 Beta measurement in mononuclear cells through real time polymerase chain reaction, 12 weeks|Changes in Expression of Inflammatory Mediators, c-Jun N-terminal kinase 1 measurement in Mononuclear cells through real time polymerase chain reaction, 12 weeks|Changes in Expression of Inflammatory Mediators, Toll-like receptor 4 measurement in mononuclear cells through real time polymerase chain reaction, 12 weeks|Changes in Expression of Inflammatory Mediators, Tumor necrosis factor alpha measurement in mononuclear through real time polymerase chain reaction, 12 weeks | Other: Change in Hypertension Mediators, Plasma concentrations measurement of Angiotensinogen through enzyme-linked immunosorbent assay, 12 weeks|Change in Hypertension Mediators, Plasma concentration measurement of Angitosensin II through enzyme-linked immunosorbent assay, 12 weeks|Change in Hypertension Mediators, Plasma concentration measurement of Renin through enzyme-linked immunosorbent assay, 12 weeks|Change in Hypertension Mediators, Plasma concentration measurement of Atrial natriuretic peptide through enzyme linked immunosorbent assay, 12 weeks|Change in Hypertension Mediators, Plasma concentration measurement of B-type natriuretic peptide through enzyme linked immunosorbent assay, 12 weeks|Change in Hypertension Mediators, Plasma concentration measurement of Cyclic guanosine monophosphate through enzyme linked immunosorbent assay, 12 weeks|Change in Hypertension Mediators, Plasma concentration measurment of Cyclic adenosine monophosphate through enzyme linked immunosorbent assay, 12 week
Sponsor/Collaborators: Sponsor: University at Buffalo | Collaborators: Kaleida Health
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 52
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2015-11
Completion Date: 2018-11
Results First Posted: 2019-10-30
Last Update Posted: 2019-10-30
Locations: ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, 14215, United States
URL: https://clinicaltrials.gov/show/NCT02433678